Ferrexpo (FXPO) shares ticked up 5.87% to 328p as it outlines decarbonisation targets
Today, the Company outlined several inaugural decarbonisation targets, including a commitment to achieve net zero carbon emissions from its operations by the year 2050.
Ferrexpo has also undertaken an initial commitment to achieve a minimum of a 30% reduction in combined Scope 1 and 2 emissions by 2030, against its baseline year for emissions (2019).
Commenting on the targets, Jim North, the Company’s Interim CEO commented: "Whilst iron ore pellets offer our customers the opportunity to significantly reduce carbon emissions already, it is important to signal a clear intention to decarbonise our own operations. It is on this basis that we have adopted the targets announced today, to demonstrate both our focus on climate change and our understanding of the importance of decarbonisation.”
Cadence Minerals (KDNC) shares soared 35.25% to 23.5p following landmark deal
Shares in Cadence Minerals jumped on Monday morning after it announced a landmark deal which will pave the way for the Company to vest an initial 20% in the Amapa Iron Ore Project.
The mineral explorer told investors that it has received confirmation from the secured bank creditors that they have obtained approval from their credit committees with respect to the proposed terms of the settlement agreement in regard to the Amapa Iron Ore Project.
Today’s approval assists in paving the way for Cadence Minerals to vest an initial 20% indirect interest in Amapa, a project consisting of an integrated mine, processing plant, railway, and privately owned port. The project, previously owned by Anglo American, has produced 6.1m tonnes of iron ore per annum, and was valued by Anglo American at US$660 million.
ReNeuron Group (RENE) shares jumped 26.05% to 119.5p as it unveils positive data
The exosome therapeutics developer unveiled positive data demonstrating clear preclinical proof-of-concept that its exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.
ReNeuron has sought to determine whether its stem cell-derived exosomes can deliver a therapeutic protein to the corpus striatum; a region of the brain affected by disabling neurological diseases such as stroke, Parkinson's Disease and Huntington's disease.
CEO Olav Hellebø, CEO, commented: "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain.”
Feedback (FDBK) shares rose 13.79% to 0.825p after signing MOU for Bleepa
Today, Feedback announced that it had signed an MOU with Quest Teleradiology to progress commercial international opportunities for its clinical communications platform, BleepaⓇ.
The firm’s new partner, Quest Teleradiology, is an Indian based diagnostic and tele-reporting teleradiology service company with healthcare customers across India, the UK and Africa.
Feedback explained that combining Bleepa with Quest's teleradiology expertise, ‘will create a blueprint for how outsourced services should be integrated into core clinical services using the Bleepa platform and will open growth opportunities for both companies in multiple markets.’